skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Imbruvica is the leading systemic therapy for relapsed/refractory CLL


While Rituxan-based therapies remain dominant in the first-line treatment setting for early- and late-stage chronic lymphocytic leukemia (CLL), the majority of patients with relapsed or refractory disease receive Imbruvica. Datamonitor Healthcare surveyed 218 hematologists and hematologist-oncologists across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain an understanding of current and future prescribing patterns for CLL. While the survey results clearly demonstrated that Rituxan-based regimens are still the foundation for the pharmacological treatment of CLL, Imbruvica is gaining increasing uptake among patients whose disease has recurred. Historically, outcomes and response rates for patients with relapsed/refractory CLL have been poor and this treatment setting has been a major area of unmet need. However, Imbruvica has gained significant uptake following its accelerated US FDA approval in February 2014 due to the drug’s superior efficacy and tolerability in patients with relapsed/refractory CLL when compared with other chemoimmunotherapy agents such as Genmab and Novartis’s Arzerra. These positive data from Imbruvica’s RESONATE trial (ClinicalTrials.gov identifier: NCT01578707) also led to its approval in the EU and Japan. As shown in the table below, Datamonitor Healthcare’s survey highlighted that physicians currently prescribe Imbruvica heavily in the relapsed/refractory CLL setting. 

 

Percentage of patients receiving Imbruvica across all surveyed markets (US, Japan, and five major EU markets), by stage and line of therapy (%)

 
 Stage   Line of Therapy   Imbruvica
 
Early-stage 
First-line
 

 5.9%

 

 First-line maintenance  10.9%
 Late-stage

First-line

 

5.8%

 

First-line maintenance 14.9% 
 Relapsed/refractory

 First-line

 

 17.8%

 

 First-line maintenance  21.9%

 

 

Source: Datamonitor Healthcare’s proprietary chronic lymphocytic leukemia survey, August 2016

 

Datamonitor Healthcare’s Chronic Lymphocytic Leukemia: Treatment reveals how CLL patients are currently managed, and outlines the disease’s greatest unmet needs.

 

 

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。